David Kirn
Chief Executive Officer at 4D Molecular Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: 4D Molecular Therapeutics Inc., 3 years.
4D Molecular Therapeutics Inc.
Director · See Remarks
Chief executive roles
4D Molecular Therapeutics Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 4, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −26,842 | $10.23 | $274,596 |
| Aug 3, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −12,415 | $10.05 | $124,722 |
| Jul 10, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −15,283 | $12.01 | $183,560 |
| Jul 10, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −442 | $12.84 | $5,673 |
| Jul 9, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −42,608 | $12.87 | $548,177 |
| Jun 22, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −114,746 | $10.47 | $1,201,391 |
| Jun 1, 2026 | 4D Molecular Therapeutics Inc. | Open-market sale | −1,922 | $10.02 | $19,258 |
| Jul 10, 2024 | 4D Molecular Therapeutics Inc. | Option exercise | +11,653 | $14.42 | $168,036 |
| Jul 10, 2024 | 4D Molecular Therapeutics Inc. | Option exercise | +1,270 | $15.78 | $20,041 |
| Jul 10, 2024 | 4D Molecular Therapeutics Inc. | Open-market sale | −12,923 | $22.49 | $290,638 |
| Jun 24, 2024 | 4D Molecular Therapeutics Inc. | Option exercise | +12,930 | $14.42 | $186,451 |
| Jun 24, 2024 | 4D Molecular Therapeutics Inc. | Open-market sale | −12,930 | $23.10 | $298,683 |
| Feb 8, 2024 | 4D Molecular Therapeutics Inc. | Open-market sale | −92,001 | $27.13 | $2,495,987 |
| Jan 23, 2024 | 4D Molecular Therapeutics Inc. | Open-market sale | −5,696 | $18.41 | $104,863 |
| Jan 5, 2024 | 4D Molecular Therapeutics Inc. | Open-market sale | −28,104 | $19.56 | $549,714 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.